 <h1>DaunoXome Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>daunorubicin liposomal</i></p><ul class="nav-tabs nav-tabs-collapse nav-tabs-pill">
<li>Overview</li>
<li><b class="nav-item here">Side Effects</b></li>
<li>Dosage</li>
<li>Interactions</li>
<li>Pregnancy</li>
<li class="nav-more">
More&lt;svg aria-hidden="true" class="ddc-icon ddc-icon-down" focusable="false" height="16" viewbox="0 0 24 24" width="16" xmlns="http://www.w3.org/2000/svg"&gt;&lt;path d="M18.5 7.94L19.56 9 12 16.56 4.44 9 5.5 7.94l6.5 6.5z"&gt;&lt;/path&gt;&lt;/svg&gt;
</li>
</ul><ul>
<li>Managing Side Effects</li>
</ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about daunorubicin liposomal. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name DaunoXome.</p><p><i>Applies to daunorubicin liposomal: intravenous dispersion</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Bone marrow suppression, bone marrow failure, agranulocytosis, neutropenia, febrile neutropenia, leucopenia, pancytopenia, thrombocytopenia, anemia, hemorrhage<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Decreased left ventricular ejection fraction</p><p><b>Uncommon</b> (0.1% to 1%): Congestive heart failure, cardiomyopathy</p><p><b>Rare</b> (less than 0.1%): Atrial fibrillation, myocardial infarction</p><p><b>Frequency not reported</b>: Shock<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Alopecia</p><p><b>Rare</b> (less than 0.1%): Palmar-plantar erythrodysesthesia syndrome<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Stomatitis, mucous ulcerations, nausea, vomiting, diarrhea, abdominal pain<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Infusion-associated reactions (e.g., back pain, flushing, chest tightness, dyspnea, allergic reaction), extravasation at the injection site (erythema, pain, swelling)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Frequency not reported</b>: Transient elevations in serum bilirubin, transient elevations in aspartate aminotransferase (AST), transient elevations in alkaline phosphatase (ALP), hepatitis, hepatic failure<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Asthenia, fatigue, fever, chills<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): infections</p><p><b>Uncommon</b> (0.1% to 1%): Sepsis, septic shock<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Dehydration<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Frequency not reported</b>: Red discoloration of urine, amenorrhea, azoospermia<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Very common</b> (10% or more): Allergic reaction</p><p><b>Rare</b> (less than 0.1%): Anaphylactic reaction<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Depression<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><h2>More about DaunoXome (daunorubicin liposomal)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Drug class: antibiotics/antineoplastics</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Advanced Reading</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Kaposi's Sarcoma</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>